Highest-materiality recent filing
InMed amends merger with Mentari; files S-4; clarifies name change, redomestication, tax treatment
Amendment clarifies sequencing: InMed will change name to Mentari Therapeutics and redomesticate to Nevada before closing.
InMed regains Nasdaq minimum bid price compliance; deficiency closed
Received Nasdaq notice on June 3, 2026 that bid price was at or above $1.00 for 10 consecutive business days (May 19–June 2).
InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company
Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
InMed amends Armistice option exercise price from $16.60 to $0.80 per share
Up to 278,761 common shares subject to options; exercise price reduced to $0.80 from $16.60.
InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit
Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.
InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80
Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.
InMed files prospectus supplement for ATM offering of common shares under existing Sales Agreement
Filed prospectus supplement dated April 3, 2026 for at-the-market equity offering.
InMed receives Nasdaq notice of bid price deficiency; 180 days to cure
Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).
InMed reports positive INM-901 data in human brain organoid neuroinflammation models
INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089
Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.
InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline
Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.
InMed shareholders re-elect all five directors, approve auditor and share issuance at AGM
All five director nominees elected with 81.9% to 82.1% support.
H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.
InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model
Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.
InMed appoints John Bathery to board; director Baldasare to depart at AGM
John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.
InMed appoints Neil Klompas to board, effective October 9, 2025
Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.
InMed announces Dec 17, 2025 annual meeting; record date Oct 22, 2025
Annual general and special meeting set for December 17, 2025.
InMed sets Dec 17, 2025 annual meeting; record date Oct 22, 2025
Annual General Meeting on December 17, 2025.
InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M
Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.
InMed to participate in H.C. Wainwright 27th Annual Global Investment Conference
Conference takes place September 8-10, 2025 in New York.
InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity
Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.
InMed Pharma raises $5M in private placement of pre-funded warrants and options
Gross proceeds ~$5M from 1,952,363 pre-funded warrants ($0.0001 exercise) and 1,952,363 preferred investment options at $2.436/share.
InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study
INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.
InMed special meeting lacks quorum for share issuance vote; appoints new auditor CBIZ
Special meeting on June 13, 2025 lacked quorum; ~60% of voted shares favored share issuance proposal but no vote held. Board evaluating next steps.
InMed Q3 FY2025 net loss $2.12M, revenue $1.26M, cash $4.68M, needs financing
Net loss of $2.12M for Q3 ended Mar 31, 2025, vs $1.72M same quarter last year; loss per share $1.94.
InMed cancels prior special meeting notice; new meeting set for June 13, 2025
Odyssey Trust Company filed amended notice to cancel prior special meeting date and record date.
InMed schedules special shareholder meeting for June 13, 2025
Special meeting set for June 13, 2025; record dates for notice and voting both April 29, 2025.
InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation
Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.
InMed Q2 net loss $2.6M, cash burn continues; BayMedica profitable amid revenue drop
Q2 net loss $2.6M vs $1.5M YoY; BayMedica revenue $1.1M (-10% YoY).
InMed selects IVT formulation for INM-089 in dry AMD; preclinical data shows 10x safety margin
Selected intravitreal (IVT) formulation for INM-089 as drug candidate for dry age-related macular degeneration (AMD).
InMed granted first PCT patent in Mexico for novel cannabinoid analog compounds
Patent No. 417531 issued in Mexico; covers novel small molecule compounds and methods of preparation.
INM-901 dose-dependently and significantly reduced pro-inflammatory cytokines TNF-α, IL-1β, and INF-γ.
InMed director Janet Grove fails re-election; resignation tendered per majority voting policy
Janet Grove received only 44.26% votes for (55.74% withheld); per policy she tendered resignation to Board chair.
InMed enters $10M standby equity facility with Yorkville; shares at 97% of VWAP
Up to $10M common shares may be sold to YA II PN, Ltd (Yorkville) at 97% of lowest daily VWAP over 3-day pricing period.
InMed publishes study on cannabinol anti-inflammatory effects in skin diseases
Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.
InMed Q1 FY2025 revenue $1.3M (+40% YoY); net loss narrows to $1.68M
BayMedica revenue $1.3M, up 40% YoY; BayMedica generated $0.3M net income (24% margin).
InMed announces 1-for-20 reverse share split to regain Nasdaq $1 bid compliance
Consolidation ratio 1:20 reduces shares from ~14.36M to ~718k on a non-diluted basis.
InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split
Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.
InMed files PCT patent application for INM-901 treating Alzheimer's and neurodegeneration
PCT patent covers composition, method of use for INM-901 in neurodegenerative diseases including Alzheimer's.
InMed to participate in Fierce Biotech webinar on Alzheimer's neuroinflammation on Nov 12, 2024
InMed (Nasdaq: INM) announced participation in Fierce Biotech webinar on November 12, 2024.
InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board
Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.
InMed FY2024 net loss $7.7M; revenue up 11% to $4.6M; cash $6.6M
Net loss of $7.7M vs $7.9M prior year; diluted EPS loss $1.01 vs $3.25.
InMed sets 2024 annual meeting for Dec 18; record date Oct 21
Annual general meeting scheduled for December 18, 2024.
InMed receives Nasdaq delisting notice for bid price non-compliance; hearing set for Oct 31, 2024
Nasdaq Staff issued delisting notice on Sept 17, 2024, after company failed to meet minimum $1.00 bid price by Sept 16, 2024 compliance deadline.
InMed Pharma issued 3 US patents for EB treatment, biosynthesis, ocular delivery
Patent for INM-755 cannabinoid topical for epidermolysis bullosa granted in US, Australia, Japan, Israel.
InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection
Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.
Long-term (7-month) in vivo study confirms cognitive and memory improvements seen in 3-month pilot using 5xFAD amyloidosis model.
InMed amends ATM equity offering agreement with H.C. Wainwright
Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.
InMed to present at Emerging Growth Conference on June 13, 2024
CEO Eric A. Adams will present a corporate overview at the Emerging Growth Conference 72.
On February 10, 2025, the Board elected to accept Ms. Grove’s resignation from the Board, including from her positions as a member of the Compensation Committee and Chair of the Nominating & Governance Committee.
Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer
appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.
As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.
The Company’s Controller, Sarah Li, has been promoted to Vice President of Accounting and Controller and Principal Accounting Officer.
On November 14, 2022, the Company terminated the Consulting Agreement for Brenda Edwards effective November 20, 2022.
the Board appointed Nicole Lemerond as a director of the Board to fill the vacancy created by Mr. Cutler’s resignation, effective as of August 8, 2022.
Adam Cutler resigned from the Board of Directors (the “Board”) (including from the Nominating & Corporate Governance Committee and the Audit Committee) of the Company, effective as of August 8, 2022.
On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s Chief Operating Officer effective July 15, 2022 (the “Effective Date”).
On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.
The Company appointed Ms. Brenda Edwards as Interim Chief Financial Officer of the Company effective April 1, 2022.
Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.
Max materiality 1.00 · Median 0.60 · Most common event other_material